Researchers at Crucell and the Scripps Research Institute have discovered a new antibody that could lead to a universal flu vaccine. According to animal test results, the antibody, CR6261,
BiondVax Pharmaceuticals has completed its first Phase II trial of Multimeric-001, its universal flu vaccine, and the results have spurred the company to begin planning its next test of the vaccine.
Thanks to the H1N1 flu virus, researchers may have found a key to developing a universal flu vaccine. According to a University of Chicago and Emory University study, people infected with H1N1 in
Developing a universal flu shot is one of the Holy Grails of the vaccine industry. But the long research road to the marketplace will be long and littered with challenging hurdles, according to
As we reported earlier, developing a universal flu vaccine is of great interest to many firms, with companies like BiondVax Pharmaceuticals and VaxInnate looking to make their marks in the field.
Dynavax (NASDAQ: DVAX) has been busy over the last few days. The Berkeley, CA-based vaccine developer says it has begun dosing its first patients in a Phase I trial of its experimental universal flu
Seattle-based Theraclone Sciences says that a team of scientists in its own ranks working in league with researchers from around the world have zeroed in on rare antibodies that have the ability to
Beheading the hemagglutinin protein exposes a stable section of the molecule, and that may just prove the solution needed to develop a universal flu vaccine, according to a team of researchers at Mt.
The venture arm of Novartis has joined a group of investors channeling $13.6 million in fresh funds for Immune Targeting Systems, which is hard at work on an experimental universal flu vaccine. ITS
The swine flu outbreak has focused a spotlight on new research underway for a universal flu vaccine. Every year vaccine experts engage in a crap shoot of sorts, trying to guess which strains of the